The “Anemocyte Run4Life” team—made up of five Anemocyte employees—took part in the 2025 Milano Marathon, choosing to support the Italian Cystic Fibrosis Research Foundation (FFC Ricerca – ETS)through the Rete del Dono fundraising platform.
read moreAnemocyte is pleased to announce the opening of its new company in the United States, Anemocyte Inc., based in Miami, Florida.
read moreAnemocyte is pleased to announce its participation in the Cell & Gene Meeting on the Med 2025, taking place from April 15th to 17th at the Rome Cavalieri in Rome.
read moreAnemocyte is excited to announce its participation in CPHI Japan 2025, taking place from April 9th to 11th at Tokyo Big Sight in Halls East 4, 5, and 6.
read moreThe international BIO-Europe Spring® conference is now in its 19th year and this year will take place in Milan at Allianz MiCo from March 17-19, 2025.
read moreThe symposium will be held in Rimini, Italy, March 17-19, involving all researchers conducting research in the field of rare genetic diseases with the Fondazione Telethon’s support.
read moreAnemocyte is excited to announce its participation in mRNA Leaders Europe, the premier event for RNA-based therapy innovations, taking place in Basel, 4-6 March 2025 at Congress Center Basel, Switzerland.
read morePlasmid manufacturing is evolving. Learn how innovations like automation, continuous processing, and AI are addressing challenges and setting new industry standards at Anemocyte.”
read morePlasmids are the unsung heroes of gene therapy, driving breakthroughs from CRISPR technology to mRNA vaccines. Explore Anemocyte’s pivotal role in advancing next-generation therapies.
read moreThe year 2024 has been a transformative period for biotechnology and gene therapy, with groundbreaking developments improving patient outcomes and expanding access to life-saving treatments.
read more
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131
VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961
